

Food and Drug Administration Silver Spring MD 20993

NDA 018972/S-041

SUPPLEMENT APPROVAL

Wyeth Pharmaceuticals, Inc. Attention: Sharada Truter, Ph.D. Manager, Worldwide Regulatory Affairs P.O. Box 8299 Philadelphia, PA 19101-8299

Dear Dr. Truter:

Please refer to your supplemental new drug application dated September 14, 2009, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Cordarone (amiodarone HCl) 200 mg Tablets.

This "Changes Being Effected" supplemental new drug application provides for labeling revised as follows:

- 1. Under ADVERSE REACTIONS/Postmarketing Reports, "eczema" has been added to the list of reported events.
- 2. The document number and revision date have been updated.

We have completed our review of this application. It is approved, effective on the date of this letter, for use as recommended in the enclosed labeling text, which is identical to the content of labeling [21 CFR 314.50(1)(1)(i)] in structured product labeling (SPL) format submitted on September 14, 2009.

LETTERS TO HEALTH CARE PROFESSIONALS

If you issue a letter communicating important safety related information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit an electronic copy of the letter to both this NDA and to the following address:

MedWatch Food and Drug Administration 5600 Fishers Lane, Room 12B05 Rockville, MD 20857

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, please call Russell Fortney, Regulatory Project Manager, at (301) 796-1068.

NDA 018972/S-041 Page 2

Sincerely,

{See appended electronic signature page}

Mary Ross Southworth, Pharm.D.
Deputy Director for Safety
Division of Cardiovascular and Renal Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

Enclosure: Content of Labeling

Type/Number	Submission Type/Number	Submitter Name	Product Name
NDA-18972	SUPPL-41	WYETH PHARMACEUTICA LS INC	CORDARONE(AMIODARONE HYDROCHLORIDE)TABLE
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.			
signature.	and time page is		
•			